Andrew McConaghie is a Senior Writer at Informa. He specializes in medicine and healthcare, with a focus on areas such as gene therapy, immunotherapy, and digital health, while also covering medical technology and pharmaceuticals. His work has been featured in Citeline, showcasing his insights into the evolving landscape of healthcare and medical innovations.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Andrew McConaghie's articles primarily focus on the healthcare and pharmaceutical industries, with a particular emphasis on scientific advancements, drug development, and industry-specific announcements. His coverage attributes indicate a reliance on press releases and data citations.
Given his focus, Andrew is likely to be interested in pitches from individuals with expert knowledge in pharmaceuticals, biopharmaceuticals, drug development processes, CAR-T therapy or immunology. He may also be receptive to pitches related to significant industry-specific announcements or groundbreaking scientific developments within the healthcare sector.
Although no specific geographic focus is mentioned for Andrew’s coverage area, it would still be beneficial for potential sources to have international expertise given the global nature of the pharmaceutical industry.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Andrew McConaghie, Jul By
Roche's head of neuroscience development Geoff Kerchner discussed latest data from its brain shuttle antibody asset trontinemab, its new Alzheimer's prevention Phase III study, and the technology's potential with other cargoes.
By: Andrew Mcconaghie
CEO Ryan Watts talks about Denali's recently approved Hunter syndrome drug Avlayah, which uses its brain-penetrant TransportVehicle technology that is also being used in candidates for Alzheimer's and other neurological conditions.
By: Andrew McConaghie, Jul By
European biotech leaders from Forbion, Complement Therapeutics and argenx discuss the challenges facing the region's companies and how a new industry initiative to boost financing and market competitiveness could help build the next generation of breakthrough firms.
By: Andrew McConaghie, Jul By
US approval for breast cancer drug giredestrant is expected later this year, but Roche's leadership has raised doubts about whether it can reach satisfactory pricing deals in Europe.
By: Andrew McConaghie, Jul By
Roche is joining Eli Lilly and Eisai/Biogen in launching a Phase III study to treat people for Alzheimer's disease before symptoms appear – with diagnostics and trial designs aimed at avoiding past failures.
By: Jul By, Andrew McConaghie
CEO Pascal Soriot said demands for price rises in Europe were “not unreasonable” as the company kept up its healthy growth in the second quarter.
A long-awaited sell-off of AI company stocks has arrived; is this also a wake-up call for big pharma's spending spree on the technology?
The specialist pharma company is looking to expand further, and aims to add more to its in-house pipeline across neuroscience, oncology and rare diseases.
By: Jul By, Andrew McConaghie
Argenx chairman and former CEO Tim Van Hauwermeiren believes Europe is not being ambitious enough for its biopharma sector, which otherwise risks being left behind by the US and China.
Competition is fierce between Ionis and Arrowhead in the emerging severe hypertriglyceridemia market, with Phase III readouts, price slashing and patent battles all in the mix. Arrowhead's CEO talks to Scrip about why he thinks new data give his firm an advantage.
